A critical overview on ticagrelor in acute coronary syndromes
2012; Oxford University Press; Volume: 106; Issue: 2 Linguagem: Inglês
10.1093/qjmed/hcs187
ISSN1460-2725
AutoresEliano Pio Navarese, Antonino Buffon, Marek Koziński, Karolina Obońska, Marcin Rychter, Vijay Kunadian, David Austin, Stefano De Servi, Adam Sukiennik, Jacek Kubica,
Tópico(s)Acute Myocardial Infarction Research
ResumoUntil a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
Referência(s)